ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
49 hedge funds and large institutions have $219M invested in Adaptimmune Therapeutics in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.34% more ownership
Funds ownership: 7.02% → 9.36% (+2.3%)
Holders
49
Holding in Top 10
1
Calls
$3K
Puts
–
Top Buyers
| 1 | +$12.7M | |
| 2 | +$11.8M | |
| 3 | +$6.56M | |
| 4 |
O
OrbiMed
New York
|
+$6.56M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$4.96M |
Top Sellers
| 1 | -$4.32M | |
| 2 | -$418K | |
| 3 | -$405K | |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$387K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$275K |